ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Radotinib, an oral BCR-ABL tyrosine kinase inhibitor, was developed as a drug for the management of chronic phase-chronic myeloid leukemia (CML-CP) in South Korea [11, 12].